Study protocol. by Tamara Mogilevski (14239682)

“…</p><p>Methods</p><p>In a single-blinded, cross-over, randomised study, healthy volunteers received on separate days corticotropin-releasing hormone (CRH, 100 μg) or normal saline (as placebo) intravenously in random order, then a HFHC meal. …”

S1 Data - by Tamara Mogilevski (14239682)

“…</p><p>Methods</p><p>In a single-blinded, cross-over, randomised study, healthy volunteers received on separate days corticotropin-releasing hormone (CRH, 100 μg) or normal saline (as placebo) intravenously in random order, then a HFHC meal. …”

pI7L inhibits the IFN-<i>γ</i>-triggered JAK-STAT signaling pathway by targeting STAT1. by Meilin Li (1832905)

Wholegrain processing and glycaemic control in type 2 diabetes: a randomised crossover trial by Sebastian Åberg (8698680)

“…</p> <p><b>Results:</b> 31 adults with type 2 diabetes (63±13 years old, BMI 32.4±7, HbA1_c 7.5±3.4% (59±14mmol/mol)) commenced the trial, 28 (90%) completed both interventions. …”

Image2_A Role of Caveolae in Trabecular Meshwork Mechanosensing and Contractile Tone.JPEG by Michael L. De Ieso (12254687)

“…Treatment with the Cav1 scaffolding domain mimetic, cavtratin (1 μM) caused a reduction in pMLC (70 ± 5% n = 7, p = 0.001), as did treatment with the scaffolding domain mutant cavnoxin (1 μM) (82 ± 7% n = 7, p = 0.04). …”

Genetic Ancestry-Smoking Interactions and Lung Function in African Americans: A Cohort Study by Melinda C. Aldrich (110234)

“…African Americans with a high proportion of African ancestry had lower baseline forced expiratory volume in one second (FEV₁) per pack-year of smoking (−5.7 ml FEV₁/ smoking pack-year) compared with smokers with lower African ancestry (−4.6 ml in FEV₁/ smoking pack-year) (interaction <em>P</em> value  = 0.17). …”

Image4_A Role of Caveolae in Trabecular Meshwork Mechanosensing and Contractile Tone.JPEG by Michael L. De Ieso (12254687)

“…Treatment with the Cav1 scaffolding domain mimetic, cavtratin (1 μM) caused a reduction in pMLC (70 ± 5% n = 7, p = 0.001), as did treatment with the scaffolding domain mutant cavnoxin (1 μM) (82 ± 7% n = 7, p = 0.04). …”

DataSheet1_Examining the paradoxical effects of kratom: a narrative inquiry.PDF by Kirsten E. Smith (10716529)

“…Five of the 10 participants met DSM-5-based criteria for kratom-use disorder (3 mild, 1 moderate, 1 severe, by symptoms counts). …”

Relationship between Circulating and Tissue microRNAs in a Murine Model of Breast Cancer by Peadar S. Waters (114309)

“…Athymic nude mice (n = 20) received either a mammary fat pad (n = 8, MFP), or subcutaneous (n = 7, SC) injection of MDA-MB-231 cells. …”

The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis by Bruno Felix-Patrício (4626616)

“…The androgen deprivation promoted several alterations in the prostate: the acinar epithelium height diminished from 16.58±0.47 to 11.48±0.29μm; the number of mast cells per field presented increased from 0.45±0.07 to 2.83±0.25; collagen fibers density increased from 5.83±0.92 to 24.70±1.56%; and acinar lumen density decreased from 36.78±2.14 to 16.47±1.31%. …”

Table 1_A retrospective analysis of 38,652 amniotic fluid karyotype.xlsx by Jianyu Ren (11429773)

“…Chromosome breakage was most common in chromosomes Y and 1, whereas deletions were most frequently detected in chromosomes X and 5. Isochromosomes mainly appeared in a mosaic form in chromosome X. …”

Image3_A Role of Caveolae in Trabecular Meshwork Mechanosensing and Contractile Tone.JPEG by Michael L. De Ieso (12254687)

“…Treatment with the Cav1 scaffolding domain mimetic, cavtratin (1 μM) caused a reduction in pMLC (70 ± 5% n = 7, p = 0.001), as did treatment with the scaffolding domain mutant cavnoxin (1 μM) (82 ± 7% n = 7, p = 0.04). …”

Data_Sheet_1_Perilymphatic fistula: a historical overview of publication trends.docx by Dianela Perdomo (13007142)

“…We hypothesized that publications on PLF have decreased in recent years relative to other inner ear disorders with overlapping symptoms.…”

Supplementary Material for: Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease by Watanabe Y. (4129684)

“…We previously reported on the comprehensive profile of the urinary proteome of AD patients and identified proteins estimated to be significantly increased or decreased in AD patients by a label-free quantification method. …”

Effects of the AMPA Antagonist ZK 200775 on Visual Function: A Randomized Controlled Trial by Richard Bergholz (244473)

“…<div><h3>Background</h3><p>ZK 200775 is an antagonist at the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and had earned attention as a possible neuroprotective agent in cerebral ischemia. …”

Epigenomic alteration of <i>Ink4a</i>-<i>Arf</i> locus. by Atsushi Kaneda (198186)

“…<i>p16</i> expression was partially increased in MEFp5, Mock and RasG12 due to stress-induced senescence during passages, but markedly increased in RasV12 cells. …”

Speed of processing training and depression in assisted and independent living: A randomized controlled trial by Marianne Smith (7512284)

“…Participants were randomized within sites to computerized SOPT vs. computerized crossword puzzles with a targeted dose of 10 hours of playtime at baseline plus 4 hours of booster training at five and eleven months. …”

Marcksb plays a key role in the secretory pathway of zebrafish Bmp2b by Ding Ye (405963)

“…In contrast, the MZ<i>marcksb</i> embryos even showed increased BMP signaling activity as measured by expression of BMP targets, phosphorylated Smad1/5/9 levels and imaging of Bmp2b, suggesting that a phenomenon of “genetic over-compensation” arose. …”

Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort by Mi Kyoung Son (3585197)

“…<div><p>Atrial fibrillation (AF) is a major risk factor for ischemic stroke and associated with a 5-fold higher risk of stroke. …”

Table 1_Obinutuzumab in systemic lupus erythematosus: a real-world experience.docx by Chunmei Wu (3202050)

“…Objectives<p>To describe the real-world efficacy and safety of obinutuzumab in a heterogeneous systemic lupus erythematosus (SLE) population, including severe or refractory manifestations.…”